1.58
+0.09(+6.04%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.49 |
| Day High | 1.64 |
| Day Low | 1.46 |
| 52-Week High | 46.68 |
| 52-Week Low | 1.41 |
| Volume | 240,076 |
| Average Volume | 261,261 |
| Market Cap | 4.55M |
| PE | -7.9 |
| EPS | -0.2 |
| Moving Average 50 Days | 1.59 |
| Moving Average 200 Days | 5.91 |
| Change | 0.09 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $16.16 as of October 31, 2025 at a share price of $1.58. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $15.88 as of October 31, 2025 at a share price of $1.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, to
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
GlobeNewswire Inc.
Oct 22, 2025 12:00 PM GMT
SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, to
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver gene